SBX 2021
Various Cancers
Early-stage ClinicalActive
Key Facts
About Stramsen Biotech
Stramsen Biotech is an early-stage, private biotech firm pioneering a plant-based drug discovery and development platform. It boasts a robust pipeline of 33 drug candidates, with 11 in early-stage clinical trials, targeting major therapeutic areas including oncology, cardiovascular disease, HIV, and diabetes. The company claims a $19 billion valuation from a third-party appraisal and is backed by lead investor GEM Global Yield LLC SCS, positioning it for significant growth as it advances candidates toward FDA submissions.
View full company profileTherapeutic Areas
Other Various Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Oncology/Immuno-oncology Portfolio | MSD | Phase III/Commercial |
| Bevacizumab Biosimilar | Dr. Reddy's Laboratories | Approved |
| LADR Platform | LadRx | Preclinical |
| NK Cell Stimulation (via JadiCell) | Therapeutic Solutions International | Preclinical |
| Zip-Code Library for Oncology | Kodikaz Therapeutic Solutions | Pre-clinical |
| Proprietary RLT Pipeline | Affibody | Not Specified (Preclinical-Phase 2) |
| Preclinical ASO Portfolio | Isarna Therapeutics | Preclinical |
| SPACE-GM Microenvironment Analysis | Enable Medicine | Research |
| Oncology Program(s) | CIS Pharma | Pre-clinical |
| Max Access Solutions (with The Max Foundation) | Tanner Pharma Group | N/A (Donation/Distribution Program) |
| CPA Platform in Oncology | InnoSIGN | Development |
| Oncology Services | Transcure Bioservices | Preclinical |